AKB-9778: Phase Ib/IIa data

An open-label, dose-escalation, U.S. Phase Ib/IIa trial in 24 patients with DME showed that once-daily subcutaneous

Read the full 163 word article

How to gain access

Continue reading with a
two-week free trial.